The Latest Breaking News from Caribou Biosciences Inc

Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability

Caribou Biosciences Inc (NASDAQ:CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).  Following a single dose at the initial dose level of 40 million CAR-T cells, a 100% complete response (CR) rate (6 of 6…

Benzinga · Jun 13, 2022

What's Going On With Caribou Biosciences Shares Today?

Caribou Biosciences, Inc. (NASDAQ: CRBU) shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematology Association 2022 Hybrid Congress.

Benzinga · Jun 10, 2022

Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study

Caribou Biosciences Inc (NASDAQ: CRBU) announced initial data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). These initial data will be shared at the European Hematology Association (EHA) 2022 Hybrid Congress.

Benzinga · May 12, 2022